Drugs / Allogeneic MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00698191 | Mar 2007 → Dec 2011 | systemic lupus erythematosus | Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00698191 ↗ |
| Known as | AlloMSC | “The purpose of this study is to evaluate the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell (AlloMSC) transplantation in patients with refractory SLE.” NCT00698191 ↗ |
| Action | Restore | “a new population of cells with capability to restore a normal immune system” NCT00698191 ↗ |
| Modality | Cell therapy | “allogeneic bone marrow derived mesenchymal stem cell (AlloMSC) transplantation” NCT00698191 ↗ |
| Route | Intravenous | “will be infused intravenously” NCT00698191 ↗ |